Evo312: An Evodiamine Analog and Novel PKCβI Inhibitor with Potent Antitumor Activity in Gemcitabine-Resistant Pancreatic Cancer,Journal of Medicinal Chemistry

当前位置： X-MOL 学术 › J. Med. Chem. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Evo312: An Evodiamine Analog and Novel PKCβI Inhibitor with Potent Antitumor Activity in Gemcitabine-Resistant Pancreatic Cancer
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2024-08-16 , DOI: 10.1021/acs.jmedchem.4c00213
Eun Seo Bae ₁ , Junhwa Hong ₂ , Yijae Lim ₂ , Woong Sub Byun ₁ , Simin Chun ₂ , Suckchang Hong _{1,

2} , Sang Kook Lee ₁

Affiliation

As an obstinate cancer pancreatic cancer (PC) poses a major challenge due to limited treatment options which include resection surgery, radiation therapy, and gemcitabine-based chemotherapy. In cancer cells, protein kinase C βI (PKCβI) participates in diverse cellular processes, including cell proliferation, invasion, and apoptotic pathways. In the present study, we created a scaffold to develop PKCβI inhibitors using evodiamine-based synthetic molecules. Among the candidate inhibitors, Evo312 exhibited the highest antiproliferative efficacy against PC cells, PANC-1, and acquired gemcitabine-resistant PC cells, PANC-GR. Additionally, Evo312 robustly inhibited PKCβI activity. Mechanistically, Evo312 effectively suppressed the upregulation of PKCβI protein expression, leading to the induction of cell cycle arrest and apoptosis in PANC-GR cells. Furthermore, Evo312 exerted an antitumor activity in a PANC-GR cell-implanted xenograft mouse model. These findings position Evo312 as a promising lead compound for overcoming gemcitabine resistance in PC through novel mechanisms.

中文翻译：

Evo312：吴茱萸碱类似物和新型 PKCβI 抑制剂，对吉西他滨耐药的胰腺癌具有有效的抗肿瘤活性

作为一种顽固性癌症，胰腺癌（PC）由于治疗选择有限（包括切除手术、放射治疗和基于吉西他滨的化疗）而构成了重大挑战。在癌细胞中，蛋白激酶 C βI (PKCβI) 参与多种细胞过程，包括细胞增殖、侵袭和凋亡途径。在本研究中，我们使用基于吴茱萸碱的合成分子创建了一个支架来开发 PKCβI 抑制剂。在候选抑制剂中， Evo312对 PC 细胞 PANC-1 和获得性吉西他滨耐药 PC 细胞 PANC-GR 表现出最高的抗增殖功效。此外， Evo312强烈抑制 PKCβI 活性。从机制上讲， Evo312有效抑制 PKCβI 蛋白表达的上调，导致 PANC-GR 细胞细胞周期停滞和凋亡。此外， Evo312在 PANC-GR 细胞植入的异种移植小鼠模型中发挥抗肿瘤活性。这些发现使Evo312成为一种有前途的先导化合物，可通过新机制克服 PC 中的吉西他滨耐药性。

更新日期：2024-08-16

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南